Tax withholding trims stake of VYNE Therapeutics Inc. (VYNE) CSO

Rhea-AI Filing Summary

VYNE Therapeutics Inc. reported that Chief Scientific Officer Stuart Iain had 15,405 shares of common stock withheld on 2026-07-23 to satisfy tax withholding tied to vesting restricted stock units. The shares were valued at $0.8976 each, and he now holds 95,944 shares directly.

Insider Trade Summary

Net Seller: 15,405 shares

Net Sell 1 txn

Insider Stuart Iain

Role CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	15,405	$0.8976	$14K

Holdings After Transaction: Common Stock — 95,944 shares (Direct)

Footnotes (1)

1. F1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

Key Figures

Shares withheld for taxes: 15,405 shares Implied share value: $0.8976 per share Direct holdings after transaction: 95,944 shares +1 more

4 metrics

Shares withheld for taxes 15,405 shares Common stock withheld to satisfy tax on RSU vesting on 2026-07-23

Implied share value $0.8976 per share Value used for the tax-withholding share disposition

Direct holdings after transaction 95,944 shares Common stock directly held by Stuart Iain following the withholding

Transaction date 2026-07-23 Date of the tax-withholding disposition reported on Form 4

Key Terms

restricted stock units, tax withholding requirements, Chief Scientific Officer

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding requirements financial

"withheld by the Issuer to satisfy tax withholding requirements"

Chief Scientific Officer other

"reporting person serves as CHIEF SCIENTIFIC OFFICER of the issuer"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/24/2026 - 05:00 PM Accepted by SEC EDGAR 07/24/2026 - 05:00 PM Learn about SEC filing dates

FAQ

What insider transaction did VYNE (VYNE) report for CSO Stuart Iain?

VYNE reported that CSO Stuart Iain had 15,405 common shares withheld on 2026-07-23 to cover tax from vesting restricted stock units. This was a tax-withholding disposition, not an open-market sale, and reflects equity compensation mechanics.

How many VYNE (VYNE) shares were withheld and at what price?

The filing shows 15,405 shares of VYNE common stock withheld at $0.8976 per share to satisfy tax obligations. This amount represents shares delivered back to the issuer rather than sold into the market for cash proceeds.

How many VYNE (VYNE) shares does Stuart Iain hold after this Form 4 event?

After the tax-withholding transaction, Stuart Iain directly holds 95,944 shares of VYNE common stock. This figure reflects his remaining direct ownership position following the RSU vesting-related share withholding reported.

Was the VYNE (VYNE) insider transaction executed under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, so this tax-withholding event is not identified as occurring under a Rule 10b5-1 trading plan. It is characterized as satisfying tax obligations from RSU vesting.

Does the VYNE (VYNE) Form 4 reflect a market sale by the CSO?

No, the Form 4 describes a tax-withholding disposition, where 15,405 shares were withheld by the issuer to meet tax requirements on RSU vesting. It does not report an open-market purchase or sale transaction by the CSO.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stuart Iain

(Last) (First) (Middle)

C/O VYNE THERAPEUTICS INC.

P.O. BOX 125

(Street)

STEWARTSVILLE NEW JERSEY 08886

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		F(1)		15,405	D	$0.8976	95,944	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

	/s/ Mutya Harsch, Attorney-in-Fact	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)